AR067513A1 - Derivados de 1,2-oxazol - Google Patents
Derivados de 1,2-oxazolInfo
- Publication number
- AR067513A1 AR067513A1 ARP080102987A ARP080102987A AR067513A1 AR 067513 A1 AR067513 A1 AR 067513A1 AR P080102987 A ARP080102987 A AR P080102987A AR P080102987 A ARP080102987 A AR P080102987A AR 067513 A1 AR067513 A1 AR 067513A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- alkyl
- dichlorophenyl
- oxazol
- alkoxy
- Prior art date
Links
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
- -1 C1-4 fluoralkyl Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- CDLLYPQXLGNEQR-UHFFFAOYSA-N (2-chloro-6-fluorophenyl)methyl n-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbamate Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1NC(=O)OCC1=C(F)C=CC=C1Cl CDLLYPQXLGNEQR-UHFFFAOYSA-N 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- GBADPCNNKASDLE-UHFFFAOYSA-N 1-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]-3-(3-imidazol-1-ylpropyl)urea Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1NC(=O)NCCCN1C=CN=C1 GBADPCNNKASDLE-UHFFFAOYSA-N 0.000 abstract 1
- BFBNTRXRJWINCQ-UHFFFAOYSA-N 1-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]-3-[3,3,3-trifluoro-2-(1h-pyrrol-2-yl)propyl]urea Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1NC(=O)NCC(C(F)(F)F)C1=CC=CN1 BFBNTRXRJWINCQ-UHFFFAOYSA-N 0.000 abstract 1
- WTCQDEKZEZSYFI-UHFFFAOYSA-N 1-[[2,6-bis(dimethylamino)phenyl]methyl]-3-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]urea Chemical compound CN(C)C1=CC=CC(N(C)C)=C1CNC(=O)NC1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl WTCQDEKZEZSYFI-UHFFFAOYSA-N 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- MYWIDJLNCRMPFP-UHFFFAOYSA-N [3-(2,5-dimethylpyrrol-1-yl)thiophen-2-yl]methyl n-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbamate Chemical compound CC1=CC=C(C)N1C1=C(COC(=O)NC=2C(=NOC=2C)C=2C(=CC=CC=2F)Cl)SC=C1 MYWIDJLNCRMPFP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula 1, en la cual R1 es hidrogeno, halo, ciano, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-3, cicloalquilo C3-6, fluoralquilo C1-4, fluoralcoxi C1-6, hidroxialquilo C1-6, alcoxi C1-3-alquilo C1-4, o cianoalquilo C1-6; cada uno de R2 y R3 es independientemente seleccionado entre halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-7, fluoralquilo C1-4, alcoxi C1-3, fluoralcoxi C1-4 y ciano; R4 es hidrogeno o alquilo C1-4 que puede estar optativamente sustituido con alcoxi C1-3, halo o ciano; R5 es halogeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4 cicloalquilo C3-6, heterocicloalquilo C3-10, fluoralquilo C1-6, fluoralcoxi C1-6, CN, alcoxi C1-3-alquilo C1-3, hidroxialquilo C1-6 o cianoalquilo C1-6; m es 0 a 3; A es NH u O; L es alquileno C1-4, donde cada hidrogeno del alquileno puede estar optativamente sustituido con R6; R6 es alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, heterocicloalquilo C3-10, fluoralquilo C1-6, fluoralcoxi C1-6, ciano, alcoxi C1-3-alquilo C1-3, hidroxialquilo C1-6 o cianoalquilo C1-6; M es arilo C6-10 o heteroarilo C5-10, cada uno de los cuales está optativamente sustituido con uno o más sustituyentes R7; R7 es hidroxi, halo, ciano, nitro, alquilo C1-6, alquinilo C2-6, alcoxi C1-6, alcoxialquilo C1-6, trifluormetoxi, difluormetoxi, fluoralquilo C1-6 mono- o polisustituido, fluoralcoxi C1-6, mono- o polisustituido, carbamoilo, sulfamoilo, cianoalquilo C1-6, fenilo, cicloalquilo C3-6, cicloalquiloxi C3-6-heterocicloalquilo C5-6, heterocicloalquiloxi C5-6, heteroarilo C5-6, alcoxicarbonilo C1-6, alcanoílo C1-6, alcanoiloxi C1-4, N-(alquil C1-6)ncarbamoílo donde n es 0 a 2, alquil C1-6S(O)a donde a es 0 a 2, fluoralquil C1-6SO2O mono- o polisustituido, NR9R10, N-alquilC1-6sulfamoílo o N,N-(alquil C1-6)2sulfamoílo; y cada uno de R9 y R10 es independientemente seleccionado entre hidrogeno y alquilo C1-4; como así también una sal aceptable para uso farmacéutico o isomero del mismo o una sal de dicho isomero; a excepcion de los compuestos: 3-[[2,6-bis(dimetilamino)fenil]metil]-1-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]urea; 1-[(2,6-diclorofenil)metil]-3-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]urea; 1-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]-3-[3,3,3-trifluor-2-(1H-pirrol-2-il)propil]urea; 1-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]-3-(3-imidazol-1-ilpropil)urea; [3-(2,5-dimetilpirrol-1-iI)tiofen-2-il]metil, N-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]carbamato; [3-(2,5-dimetilpirrol-1-il)tiofen-2-il]metil N-[3-(2-cloro-6-fluor--fenil)-5-metil-1,2-oxazol-4-il]carbamato; (2,3,4,5,6-pentametilfenil)metil N-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]carbamato; (2-cloro-6-fluor-fenil)metil N-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]carbamato: (3,5-diclorofenil)metil N-[3-(2,6-diclorofenil)-5-metil-1,2-0xazol-4-iI]carbamato; y (2,6-dicloropiridin-4-il)metil N-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]carbamato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94966507P | 2007-07-13 | 2007-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067513A1 true AR067513A1 (es) | 2009-10-14 |
Family
ID=39709355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102987A AR067513A1 (es) | 2007-07-13 | 2008-07-11 | Derivados de 1,2-oxazol |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR067513A1 (es) |
| CL (1) | CL2008002038A1 (es) |
| PE (1) | PE20090477A1 (es) |
| TW (1) | TW200911766A (es) |
| UY (1) | UY31219A1 (es) |
| WO (1) | WO2009010784A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013005889A2 (pt) * | 2010-09-13 | 2020-08-25 | Novartis Ag | triazinaoxadiazóis, composição farmacêutica que os compreende e uso dos mesmos |
| MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| AU2013266398A1 (en) | 2012-05-22 | 2015-01-22 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| BR112015000187A2 (pt) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| CA2898679A1 (en) | 2013-03-14 | 2014-09-25 | Xenon Pharmaceuticals Inc. | Substituted triazolopyridines and methods of use thereof |
| RU2015143834A (ru) | 2013-03-15 | 2017-04-24 | Дженентек, Инк. | Замещенные бензоксазолы и способы их применения |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| WO2015102929A1 (en) | 2013-12-30 | 2015-07-09 | Novartis Ag | Tricyclic sulfonamide derivatives |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CA2986045A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MA46546A (fr) | 2016-10-17 | 2021-05-05 | Genentech Inc | Composés thérapeutiques et leurs procédés d'utilisation |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
-
2008
- 2008-07-09 TW TW097125959A patent/TW200911766A/zh unknown
- 2008-07-09 WO PCT/GB2008/050554 patent/WO2009010784A1/en not_active Ceased
- 2008-07-11 UY UY31219A patent/UY31219A1/es unknown
- 2008-07-11 PE PE2008001166A patent/PE20090477A1/es not_active Application Discontinuation
- 2008-07-11 CL CL2008002038A patent/CL2008002038A1/es unknown
- 2008-07-11 AR ARP080102987A patent/AR067513A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20090477A1 (es) | 2009-05-24 |
| WO2009010784A1 (en) | 2009-01-22 |
| UY31219A1 (es) | 2009-03-02 |
| TW200911766A (en) | 2009-03-16 |
| CL2008002038A1 (es) | 2009-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067513A1 (es) | Derivados de 1,2-oxazol | |
| PE20081447A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR074459A1 (es) | Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| PE20091370A1 (es) | Arilpirrolinas insecticidas | |
| PE20120655A1 (es) | Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map) | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| PE20140412A1 (es) | Inhibidores de glucosilceramida sintasa | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |